Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000433
UniProt IDQ02641
Primary gene name(s)CACNB1
Synonym gene name(s)CACNLB1
Protein nameVoltage-dependent L-type calcium channel subunit beta-1
Protein functionThe beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Subcellular locationCell membrane, sarcolemma;
Peripheral membrane protein;
Cytoplasmic side.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q02641
Gene Ontology
(Biological Process)
Complete annatation
cardiac conduction [GO:0061337];
chemical synaptic transmission [GO:0007268];
neuromuscular junction development [GO:0007528];
regulation of voltage-gated calcium channel activity [GO:1901385];
transport [GO:0006810]
Gene Ontology
(Molecular Function)
Complete annatation
high voltage-gated calcium channel activity [GO:0008331];
voltage-gated calcium channel activity [GO:0005245]
Gene Ontology
(Cellular Component)
Complete annatation
plasma membrane [GO:0005886];
sarcolemma [GO:0042383];
voltage-gated calcium channel complex [GO:0005891]
Protein-protein interaction107236
Phylogenetic treeQ02641
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.07846652311962330.8810968597293830.922342816352359
AZA vs. DISU-0.08009251810195120.7544360858673890.976021571236163
AZA vs. IL7-0.0223517219178390.9098648269676460.999311006273513
AZA vs. SAHA0.4271117501073280.08466401753073780.363546718688464
DISU vs. CD3-0.0144873364275390.9779774416437450.986405088062208
DISU vs. IL70.04750901148782850.8520548267823390.970365378389648
DISU vs. SAHA0.5101608989753080.08305048694963290.366194818261532
DMSO vs. AZA0.124889143014560.4691652995618641
DMSO vs. CD30.1927596747634480.707928183124540.78620995788951
DMSO vs. DISU0.2034613252663170.4096986279633880.870383340329923
DMSO vs. IL7-0.1398734862834790.4467945351558150.867967476478598
DMSO vs. SAHA0.2973461398005080.2128901742351080.555675063369815
HIV vs. Mock in Activation0.5439911670610590.5921268581802470.999983755607037
HIV vs. Mock in Latency0.1568043492421020.354871490817190.999834320637052
IL7 vs. CD30.05938393791280810.9092996816243310.942502688840843
SAHA vs. CD30.4828209716701750.3598687156722280.476724819372405
SAHA vs. IL70.4481219288498380.06969356247894520.229229928170984
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.291939 0.105818
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00308 Ibutilide approved yes activator
DB01388 Mibefradil withdrawn yes inhibitor
DB00653 Magnesium Sulfate approved, vet_approved unknown unknown
DB00661 Verapamil approved yes inhibitor
DB04855 Dronedarone approved unknown unknown
DB00393 Nimodipine approved yes inhibitor
DB00898 Ethanol approved unknown unknown
DB00421 Spironolactone approved unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04010 MAPK signaling pathway - Homo sapiens (human)
hsa04260 Cardiac muscle contraction - Homo sapiens (human)
hsa04261 Adrenergic signaling in cardiomyocytes - Homo sapiens (human)
hsa04921 Oxytocin signaling pathway - Homo sapiens (human)
hsa05410 Hypertrophic cardiomyopathy (HCM) - Homo sapiens (human)
hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human)
hsa05414 Dilated cardiomyopathy - Homo sapiens (human)
Menu